Prescription Weight Loss Medication | Wegovy® (semaglutide) …
Lose weight & keep it off for adults and children aged ≥12 years with obesity, or some adults with overweight and weight-related medical problems.
Novo Nordisk CEO says he's confident about Wegovy supply, …
8 hours ago · Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply improving this year, and brushed off fears of the company falling behind Eli Lilly & Co. Details about its next-generation weight loss drugs ...
Chronic Weight Results | Wegovy® (semaglutide) injection 2.4 mg
Wegovy ® is the only GLP-1 RA proven to sustain ~15% mean weight loss at 2 years
Wegovy® (semaglutide) injection 2.4 mg Official Physician Site
Wegovy (semaglutide) injection 2.4 mg is indicated for chronic weight management for adults with obesity and to reduce the risk of major adverse cardiovascular events in adults with obesity or overweight and cardiovascular disease. Read Important Safety and Prescribing Info, including Boxed Warning.
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss …
Jan 17, 2025 · A high dose of Novo Nordisk’s obesity drug Wegovy caused more weight loss than the approved regimen in a Phase III trial, the company said Friday. However, the data suggest Eli Lilly’s rival GLP-1 drug Zepbound may still have an edge over Wegovy.
Novo touts weight loss results in high-dose Wegovy study
Jan 17, 2025 · In the phase 3b STEP UP study, an experimental 7.2-mg semaglutide dose helped patients lose more weight on average at 72 weeks compared to placebo or semaglutide 2.4 mg, which is currently...
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Jan 17, 2025 · Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli...
Novo Nordisk’s high-dose Wegovy increases weight loss and …
Jan 20, 2025 · Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically...
Novo Nordisk’s Wegovy Sustains Weight Loss for Four Years ... - BioSpace
May 14, 2024 · Novo Nordisk ’s blockbuster GLP-1 analog Wegovy (semaglutide) can maintain meaningful weight loss for up to four years and improve cardiovascular health regardless of the amount of weight lost, according to two studies presented at …
In obesity trial, Novo Nordisk hits the mark with oral Wegovy
May 23, 2023 · In the study, patients who received a 50 mg daily dose of the treatment lost an average of 15.1% of their weight over 68 weeks, compared with a 2.4% average weight loss for those on...